NIH Director Dr. Jay Bhattacharya on Cost, Science, and Prevention
Alzheimer’s disease costs the United States more than $800 billion a year. Medical care makes up only a fraction of it. Families bear the rest through lost wages, unpaid caregiving, and memory care that insurance often doesn’t cover.
Dr. Jay Bhattacharya, a physician and economist who now leads the National Institutes of Health (NIH), says that figure makes a strong and compelling case for getting ahead of the disease.
In this episode, he shares why Alzheimer’s research is opening up to new ideas, why treatments help some patients more than others, and why he sees independent replication, not authority, as the true guidepost for science.
In This Episode:
Your Host: Emily Kaplan
Our Guest: Dr. Jay Bhattacharya, Director of the National Institutes of Health, Professor Emeritus of Health Policy at Stanford University, physician, and health economist
This Episode Explores:
- Why is Alzheimer’s research looking beyond amyloid?
- Why do Alzheimer’s drugs work for some people but not others?
- How does Alzheimer’s risk differ for women?
- Why does Dr. Bhattacharya say a blood test “is not your fate”?
- Which habits now have scientific backing for brain health?
- How can replication rebuild trust in Alzheimer’s research?
Why Alzheimer’s Research Is Looking Beyond Amyloid
For decades, one theory shaped Alzheimer’s research: Buildups of amyloid and tau proteins in the brain cause the disease. Dr. Bhattacharya calls it “a completely reasonable hypothesis,” but he says the real picture is “a much more complicated condition,” shaped by aging, genetics, and factors scientists don’t yet understand.
Since becoming NIH director, he’s watched the field broaden the ideas it tests. In his view, that openness is already leading to progress.
Personalized Answers for Alzheimer’s Patients
Today’s FDA-approved drugs can clear amyloid from the brain almost completely. Some patients, like Dr. Brent Beasley, respond well. Others see little change. Dr. Bhattacharya calls that difference “a central scientific question.”
The NIH aims to find answers that fit each person’s genetics and physiology. That work includes research on why women, who make up about two-thirds of people with Alzheimer’s, may face unique risks due to biological differences from men.
That individual view extends to testing. When Dr. Bhattacharya trained as a medical student in the 1990s, doctors could confirm Alzheimer’s only through an autopsy. He calls today’s blood tests “magical,” but his message for anyone facing a positive result is clear: “The blood test is not your fate.”
How the NIH Wants to Restore Trust in Science
When one hypothesis dominates a field, Dr. Bhattacharya says, the researchers behind it can control who gets funding and promotions. As a result, Alzheimer’s research has faced major scandals, and he calls fraud “only a symptom of the problem.” The deeper issue is a culture that treats authority, not replication, as the standard of truth.
To change that, the NIH plans to launch a journal for replication studies, where original authors can’t block results that challenge their work. Dr. Bhattacharya welcomes that same scrutiny of his own research: “If you check my work…that’s an honor for me.”
Watch the episode to hear why Dr. Bhattacharya says there’s “no such thing as ‘trust the science,’” what he learned as acting director of the CDC, and how the NIH balances prevention research with the search for a cure.
Common Questions About Alzheimer’s Research, Testing, and Prevention
What is the amyloid hypothesis?
The amyloid hypothesis proposes that buildups of amyloid protein in the brain drive Alzheimer’s disease. Drugs that clear amyloid can slow decline for some patients. Many researchers now believe Alzheimer’s has several possible pathways, including genetics, aging, and other biological changes.
How much does Alzheimer’s disease cost in the United States?
A USC-led study estimates dementia will cost the United States $818 billion in 2026. Medical care accounts for only part of that total. Families carry much of the cost through unpaid caregiving, lost work, and long-term care such as memory care units.
Does a positive Alzheimer’s blood test mean you will develop dementia?
No. A positive result signals risk, but it doesn’t predict how or when the disease will progress, and false positives can occur. A doctor can interpret results in context and help plan next steps. Learn more about how these tests work from Dr. Jeff Burns.
Why are women more likely to develop Alzheimer’s?
Women make up about two-thirds of people with Alzheimer’s. Longer life spans explain part of that gap, but researchers also study hormonal changes, such as the drop in estrogen during menopause. The NIH funds research on how the disease develops differently in women and men.
Can lifestyle changes lower the risk of dementia?
Ralph recommends patience and an honest conversation. His wife’s persistence moved him to see a primary care provider, and he urges families not to accept “it’s just old age” as the final answer. Ralph also notes that more people now want to know their diagnosis, and more treatment options exist than when he first started his Alzheimer’s journey.